UK Clinical Research Network : Portfolio Database User Guide  
Welcome to the UK Clinical Research Network Study Portfolio : NIHR (England)  


NB: The information displayed below does not replace the protocol. The latest protocol version should always be consulted before making clinical decisions.
DRN 660 (Paraoxonase and HDL qualities in glycaemia and inflammation)

Changes in paraoxonase activity, HDL properties, inflammatory markers and corneal innervation in post-bariatric surgery patients, type 1 diabetics with and without nephropathy, type 2 diabetics, and during an oral glucose tolerance test.

Specialty
Diabetes (co-adopted by Cardiovascular, Surgery)
Portfolio Eligibility
Automatically eligible
ISRCTN
EudraCT
MREC N°
UKCRN ID 11607
WHO ID
Research Summary
Study Type Both
Design Type Treatment, Cohort study
Disease(s) Retinopathy
Neuropathy
Cardiovascular disease
Dyslipidaemia
Metabolic
Obesity
Cardiovascular Prevention
Phase Experimental Medicine
Current Status Open
Closure Date 12/31/2018
Global Sample Size 720
Global Recruitment to Date
  10%
Geographical Scope UK Multi-Centre
Lead Country England
Open to new sites No
Main Inclusion Criteria
Patients with Type 1 diabetes who are not receiving lipidlowering drugs, omega fatty acid supplements or thiazolidinediones and without clinical and/or ECG evidence of CHD. Type 2 diabetic patients who are not receiving omega fatty acid supplements or thiazolidinediones and without clinical and/or ECG evidence of CHD. Patients with impaired fasting glucose undergoing oral glucose tolerance test. Patients scheduled for bariatric surgery. Healthy controls who have no major acute or chronic illness, are not receiving regular medication and not taking omega fatty acid supplements, do not have clinically overt ischaemic heart disease. Subjects (male and female) aged between 20 and 75. Subjects who have capacity and understanding for informed consent process.
Main Exclusion Criteria
Type 1 diabetics using lipid lowering therapy, thiazolidinediones, omega fatty acid supplements. History and/or ECG evidence of ST segment changes indicative of CHD. Type 2 diabetics receiving thiazolidinediones, omega fatty acid supplements. History and/or ECG evidence of ST segment changes indicative of CHD. Healthy controls who have any history of CHD, vascular insufficiency, or diabetes. Use of any lipid-lowering drug or omega fatty acid supplements.
Chief Investigator(s)
Prof Handrean Soran
Further details, please contact
Dr See Kwok

Manchester Royal Infirmary

Manchester Royal Infirmary
Oxford Road
Manchester
Greater Manchester
M13 9WL
UNITED KINGDOM

Tel: 1612764682
sk7@doctors.org.uk
Funder(s) British Heart Foundation (BHF)
Juvenile Diabetes Research Foundation Limited (JDRF)
Sponsor(s) Central Manchester Unversity Hospitals NHS Foundation Trust (CMFT)




england.ukcrn.org.uk/search
If you experience problems using the application, please click here.